Gene: MECOM

2122
AML1-EVI-1|EVI1|KMT8E|MDS1|MDS1-EVI1|PRDM3|RUSAT2
MDS1 and EVI1 complex locus
protein-coding
3q26.2
Ensembl:ENSG00000085276 MIM:165215 Vega:OTTHUMG00000158596 UniprotKB:Q03112
NG_028279.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.177e-1 (AD)  9.193e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg02556393chr3:168866705MECOM2.800e-24Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MYCT10.914
TGFBR20.9
MYOF0.893
FLI10.893
FOXC10.891
EMCN0.876
CFH0.874
CASP100.867
CYYR10.866
LEF10.866

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ASPDH-0.53
HAS1-0.518
MARCH4-0.518
MYADML2-0.514
SLC7A4-0.513
SPEF1-0.512
LRRC73-0.503
LRTM2-0.503
CORT-0.503
BCL11A-0.503

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0065512-amino-2-methyl-1-propanol2-amino-2-methyl-1-propanol results in decreased expression of MECOM mRNA25088246
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA"27188386
D000079AcetaldehydeAcetaldehyde affects the expression of MECOM mRNA22634333
D000082AcetaminophenAcetaminophen results in decreased expression of MECOM mRNA21420995|2906747
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of MECOM gene27153756
D000535Aluminum[APP protein modified form binds to Aluminum] which results in decreased expression of MECOM mRNA21298039
C059765amphotericin B, deoxycholate drug combination"amphotericin B, deoxycholate drug combination results in increased expression of MECOM mRNA"22863853
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of MECOM mRNA24449571
D001151ArsenicArsenic affects the methylation of MECOM gene25304211
C006632arsenic trioxidearsenic trioxide results in decreased expression of MECOM mRNA20458559|2494460
C006632arsenic trioxidearsenic trioxide results in decreased expression of MECOM protein24944602
C006632arsenic trioxidearsenic trioxide results in increased localization of [MECOM protein co-treated with SUMO1 protein]23770046
C006632arsenic trioxidearsenic trioxide results in increased sumoylation of MECOM protein23770046
C006632arsenic trioxideMECOM protein results in increased susceptibility to arsenic trioxide15203277
D001280AtrazineAtrazine results in increased expression of MECOM mRNA22378314
C030935benz(a)anthracenebenz(a)anthracene results in decreased expression of MECOM mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MECOM mRNA26001963
D001564Benzo(a)pyreneBenzo(a)pyrene affects the expression of MECOM mRNA21714911
C006780bisphenol Abisphenol A results in decreased expression of MECOM mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of MECOM gene28505145
C018475butyraldehydebutyraldehyde results in decreased expression of MECOM mRNA26079696
C054133casticincasticin results in decreased expression of MECOM mRNA28444820
D019327Copper SulfateCopper Sulfate results in increased expression of MECOM mRNA19549813
D002945CisplatinCisplatin results in decreased expression of MECOM mRNA22023808
D004008DiclofenacDiclofenac results in decreased expression of MECOM mRNA26934552
D002117CalcitriolCalcitriol results in decreased expression of MECOM mRNA16002434
C118739entinostatentinostat results in decreased expression of MECOM mRNA26272509
C118739entinostatentinostat results in increased expression of MECOM mRNA27188386
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA"27188386
C061365flusilazoleflusilazole affects the expression of MECOM mRNA22634333
C061365flusilazoleflusilazole results in increased expression of MECOM mRNA28263823
D017313FenretinideFenretinide results in increased expression of MECOM mRNA28973697
D006918HydroxyureaHydroxyurea results in increased expression of MECOM protein mutant form16532439
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MECOM mRNA26378955
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of MECOM mRNA28001369
D008769MethylnitronitrosoguanidineMethylnitronitrosoguanidine results in increased expression of MECOM mRNA12634122
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of MECOM mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of MECOM mRNA"25554681
C570897NSC668394NSC668394 results in decreased expression of MECOM mRNA27137931
C496932panobinostatpanobinostat results in decreased expression of MECOM mRNA26272509
D010634PhenobarbitalPhenobarbital affects the expression of MECOM mRNA23091169
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of MECOM mRNA19710929
D011374ProgesteroneProgesterone results in increased expression of MECOM mRNA23012394
C017947sodium arsenitesodium arsenite affects the methylation of MECOM gene28589171
C017947sodium arsenitesodium arsenite results in increased expression of MECOM mRNA22714537
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MECOM mRNA26378955
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of MECOM mRNA11489354
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MECOM mRNA24058054|2637764
D019284ThapsigarginThapsigargin results in decreased expression of MECOM mRNA22378314
D013849ThimerosalThimerosal results in increased expression of MECOM mRNA27188386
C009495titanium dioxidetitanium dioxide results in increased expression of MECOM mRNA23557971
D014050TolueneToluene results in increased expression of MECOM mRNA22967744
D014212TretinoinTretinoin results in increased expression of MECOM mRNA21934132|2383079
D014212TretinoinTretinoin results in increased stability of and results in increased expression of MECOM mRNA16014322
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of MECOM mRNA24935251|2627250
D014415TunicamycinTunicamycin results in decreased expression of MECOM mRNA22378314
D014635Valproic AcidValproic Acid affects the expression of MECOM mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of MECOM mRNA23179753
D014635Valproic AcidValproic Acid results in decreased methylation of MECOM gene29154799
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of MECOM gene25560391
C029297vinylidene chloridevinylidene chloride results in decreased expression of MECOM mRNA26682919

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0003677DNA binding-ISS-  
GO:0003700DNA-binding transcription factor activity-IDA19767769  
GO:0005515protein binding-IPI10856240  11328817  11568182  17635584  21555002  22308434  
25814554  
GO:0018024histone-lysine N-methyltransferase activity-TAS-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006351transcription, DNA-templated-IEA-  
GO:0006357regulation of transcription by RNA polymerase II-IEA-  
GO:0006915apoptotic process-IEA-  
GO:0030154cell differentiation-IEA-  
GO:0034968histone lysine methylation-IEA-  
GO:0043069negative regulation of programmed cell death-IMP10856240  
GO:0045892negative regulation of transcription, DNA-templated-IDA10856240  11568182  
GO:0045893positive regulation of transcription, DNA-templated-IDA11568182  19767769  
GO:0046329negative regulation of JNK cascade-IMP10856240  
GO:0051726regulation of cell cycle-IDA11568182  
GO:0071425hematopoietic stem cell proliferation-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000118histone deacetylase complexcolocalizes_withIDA11568182  
GO:0005634nucleus-IDA15897867  
GO:0005654nucleoplasm-TAS-  
GO:0005829cytosol-TAS-  
GO:0016607nuclear speck-IDA11568182  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa05200Pathways in cancer
hsa05220Chronic myeloid leukemia
Reactome ID Reactome Term Evidence
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-1257604PIP3 activates AKT signalingIEA
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-3214841PKMTs methylate histone lysinesTAS
R-HSA-3247509Chromatin modifying enzymesTAS
R-HSA-4839726Chromatin organizationTAS
R-HSA-6807070PTEN RegulationTAS
R-HSA-6807070PTEN RegulationIEA
R-HSA-8943724Regulation of PTEN gene transcriptionTAS
R-HSA-8943724Regulation of PTEN gene transcriptionIEA
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006925Intracellular signaling by second messengersIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28114305Targeted Sequencing of Lung Function Loci in Chronic Obstructive Pulmonary Disease Cases and Controls. (2017)Artigas MSPLoS One
25189868Gene-smoking interactions identify several novel blood pressure loci in the Framingham Heart Study. (2015 Mar)Sung YJAm J Hypertens